基本信息
浏览量:181
职业迁徙
个人简介
Akslen´s team, and now CCBIO, are engaged in translational cancer research with a strong focus on exploration and validation of novel biomarkers for more biologically based classification and grading of malignant tumors, as a better guide for targeted treatment. The group has included projects on various cancers, such as breast cancer, malignant melanoma, prostate cancer, and gynecologic cancers. Studies of human tumor samples are combined with experimental cell and animal models to improve translation. The overall aim is to provide novel biomarkers which can assist in prediction of aggressive tumor behavior and be helpful in tailored treatment.
研究兴趣
论文共 416 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
British Journal of Cancerno. 1 (2024): 99-107
Scientific Reportsno. 1 (2023): 1-13
Cancersno. 20 (2023): 5106-5106
引用0浏览0WOS引用
0
0
SCANDINAVIAN JOURNAL OF PUBLIC HEALTHno. 3 (2023): 403-411
BIOINFORMATICS ADVANCESno. 1 (2023)
EBIOMEDICINE (2023): 104595-104876
Cancer medicineno. 17 (2023): 17891-17900
Inge Morild,Lars A. Akslen,Anders Molven, Kathrine Skarstein, Bjorn I. Bertelsen,Sverre Mork, Ole Petter F. Clausen
TIDSSKRIFT FOR DEN NORSKE LAEGEFORENINGno. 5 (2023): 467-467
引用0浏览0引用
0
0
Silje Kjølle,Kenneth Finne,Even Birkeland, Vandana Ardawatia, Ingeborg Winge,Sura Aziz,Gøril Knutsvik,Elisabeth Wik,Joao A. Paulo,Heidrun Vethe,Dimitrios Kleftogiannis,Lars A. Akslen
Nature Communicationsno. 1 (2023): 1-16
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn